Hansoh Pharmaceutical Group

Diversified pharma

3692 · HKEX · China

Public Market Listing

3692HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Hansoh Pharmaceutical Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(17 total)
17Total Assets
1Approved
10Phase 3 / Filed
6Phase 1–2 / Early
16Diseases
Quick filter:
Showing 17 of 17 assets
Target & Modality
Approved
CD19Monoclonal antibody
Systemic Lupus ErythematosusMyasthenia Gravis
Generalized Myasthenia Gravis
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 3
TYK2Small molecule
Psoriatic ArthritisPsoriasis
Phase 3
Dopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Small molecule
Schizophrenia
Phase 3
IL-23 p19Monoclonal antibody
Psoriasis
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 DiabetesHidradenitis Suppurativa
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes
Phase 3
Erythropoietin receptor (EPO-R)Peptide
Chronic Kidney Disease
Phase 3
B7-H3Antibody–drug conjugate
Non-Small Cell Lung CancerSmall Cell Lung CancerEsophageal Cancer
Esophageal Squamous Cell Carcinoma
Phase 3
Calcium-sensing receptor (CaSR)Small molecule
Chronic Kidney Disease
Phase 3
HBV polymerase (reverse transcriptase)Small molecule
Chronic Hepatitis B
HS-10353No recent activity
Phase 2
GABA-A receptorSmall molecule
Major Depressive Disorder
Phase 2
Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule
Chronic Kidney Disease
Phase 2
IL-23 receptorPeptide
Psoriasis
Phase 1
Undisclosed / early pipelineSmall molecule
Schizophrenia

Upcoming events

(26 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (10)
February 2027 (1)
HS-20118Phase 2Moderate to Severe Plaque Psoriasis
Est. primary completion 2027-02-28 · NCT07765628 · CT.gov ↗
What to watch
March 2027 (4)
HS-20137Phase 2Moderate-to-severe Plaque Psoriasis
Est. primary completion 2027-03-01 · NCT07879885 · CT.gov ↗
What to watch
olatorepatidePhase 3Type 2 Diabetes
Est. primary completion 2027-03-30 · NCT07156500 · CT.gov ↗
What to watch
olatorepatidePhase 3Type 2 Diabetes
Est. primary completion 2027-03-30 · NCT07156539 · CT.gov ↗
What to watch
HS-20137Phase 3Moderate-to-severe Plaque Psoriasis
Est. primary completion 2027-03-31 · NCT06844799 · CT.gov ↗
What to watch
April 2027 (1)
InebilizumabPhase 2Neuromyelitis Optica Spectrum Disorder
Est. primary completion 2027-04-13 · NCT05549258 · CT.gov ↗
What to watch
November 2027 (4)
Risvutatug rezetecanPhase 1/2Sarcoma
Est. primary completion 2027-11-05 · NCT07602777 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Neoplasms, Lung
Est. primary completion 2027-11-05 · NCT07099898 · CT.gov ↗
What to watch
HS-10390Phase 2Chronic Kidney Disease
Est. primary completion 2027-11-11 · NCT07555054 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Limited-stage Small-cell Lung Cancer
Est. primary completion 2027-11-30 · NCT06526624 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
olatorepatidePhase 2Overweight or Obesity
Est. primary completion 2028-01-21 · NCT07685808 · CT.gov ↗
What to watch
March 2028 (1)
Risvutatug rezetecanPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-03-30 · NCT07824882 · CT.gov ↗
What to watch
July 2028 (1)
HS-10380Phase 3SCHIZOPHRENIA 1 (Disorder)
Est. primary completion 2028-07-31 · NCT07759869 · CT.gov ↗
What to watch
August 2028 (1)
InebilizumabPhase 2Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
November 2028 (1)
olatorepatidePhase 2Hidradenitis Suppurativa
Est. primary completion 2028-11-24 · NCT07830329 · CT.gov ↗
What to watch
December 2028 (2)
olatorepatidePhase 3Overweight or Obesity Without Diabetes
Est. primary completion 2028-12-19 · NCT07896265 · CT.gov ↗
What to watch
Risvutatug rezetecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07464327 · CT.gov ↗
What to watch
2029 (4)
January 2029 (2)
Risvutatug rezetecanPhase 1/2Gastrointestinal Neoplasms
Est. primary completion 2029-01-09 · NCT06885034 · CT.gov ↗
What to watch
HS-10380Phase 3SCHIZOPHRENIA 1 (Disorder)
Est. primary completion 2029-01-24 · NCT07911787 · CT.gov ↗
What to watch
June 2029 (1)
Risvutatug rezetecanPhase 1/2Neoplasms, Lung
Est. primary completion 2029-06-22 · NCT07602855 · CT.gov ↗
What to watch
December 2029 (1)
Risvutatug rezetecanPhase 3Neoplasms, Prostate
Est. primary completion 2029-12-05 · NCT07802704 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
InebilizumabPhase 2Generalized Myasthenia Gravis
Est. primary completion 2030-03-13 · NCT06987539 · CT.gov ↗
What to watch
December 2030 (1)
Risvutatug rezetecanPhase 3Esophageal Squamous Cell Carcinoma (ESCC)
Est. primary completion 2030-12-31 · NCT07621601 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
InebilizumabPhase 2Immunoglobulin G4-related Disease
Est. primary completion 2031-06-10 · NCT07222553 · CT.gov ↗
What to watch
July 2031 (1)
InebilizumabPhase 3Autoimmune Hepatitis, AIH
Est. primary completion 2031-07-30 · NCT07598825 · CT.gov ↗
What to watch
September 2031 (1)
InebilizumabPhase 3Glomerulonephritis, Membranous
Est. primary completion 2031-09-27 · NCT07851220 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(12)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 September 2026Topline resultHS-10374Pivotal Phase 3 of HS-10374 in plaque psoriasis meets both co-primary endpoints
Hansoh Pharmaceutical Group · Source ↗
2 September 2026Filing acceptedRisvutatug rezetecanChina's NMPA accepts the BLA for HS-20093 (risvutatug rezetecan) in small cell lung cancer
CN, NMPA · Hansoh Pharmaceutical Group · Source ↗
10 July 2026Topline resultRisvutatug rezetecan (HS-20093 / GSK5764227)ARTEMIS-008 Phase 3: overall survival primary endpoint met in relapsed small cell lung cancer
Hansoh Pharmaceutical Group · Source ↗
9 June 2026Filing acceptedSHR6508NMPA accepts the NDA for HS-10568 (SHR6508) in secondary hyperparathyroidism of CKD on hemodialysis
China, NMPA · Hansoh Pharmaceutical Group Company Limited · Source ↗
June 2026Filing acceptedolatorepatideNMPA accepts olatorepatide NDA
CN, NMPA · Hansoh Pharma · Source ↗
9 March 2026Topline resultolatorepatidePositive Phase 3 topline results for olatorepatide in Chinese adults with obesity
7 March 2026Topline resultolatorepatidePhase 3 study of olatorepatide (HS-20094) in China met its co-primary endpoints at week 48
CN · Hansoh Pharma · Source ↗
12 February 2026ApprovalInebilizumabEuropean Commission approves UPLIZNA for generalized myasthenia gravis
EU, EC · Source ↗
11 December 2025ApprovalInebilizumabFDA approves UPLIZNA for generalized myasthenia gravis
US, FDA · Amgen · Source ↗
3 April 2025ApprovalInebilizumabFDA approves UPLIZNA for IgG4-RD
US, FDA · Source ↗
15 October 2024Topline resultInebilizumabMINT Phase 3 primary results
Amgen · Source ↗
5 June 2024Topline resultInebilizumabMITIGATE (NCT04540497) Phase 3 met its primary endpoint
Amgen · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$1.0B$199M$3.8B—report ↗

Hansoh Pharmaceutical Group reported revenue of $1,025.71M, R&D spend of $198.81M, and cash and equivalents of $3,783.79M for H1 2025.

Figures only: this period's report disclosed no narrative text

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.1B$468M$4.5B—report ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.7B$376M$3.1B—report ↗
2023-FY$1.4B$297M$3.2B—report ↗
2022-FY$1.4B$252M$2.5B—report ↗
2021-FY$1.5B$279M$2.3B—report ↗
2020-FY$1.3B$182M$657M—report ↗